Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Outcomes in COVID-19 remdesivir studies
Outcomes in remdesivir studies. Studies show significantly increased risk of acute kidney injury [Gérard, Zhou].
0 0.5 1 1.5+ All studies 14% 42 129,784 Improvement, Studies, Patients Relative Risk Mortality 16% 38 128,385 Ventilation -24% 7 32,601 ICU admission -34% 2 2,163 Hospitalization -17% 3 2,658 Progression 47% 2 12,659 Recovery 24% 2 1,188 Viral clearance 0% 1 142 RCTs 13% 8 8,887 RCT mortality 8% 7 8,325 Peer-reviewed 8% 34 118,784 Early 61% 4 1,324 Late 14% 39 128,832 Remdesivir for COVID-19 c19early.com/s Oct 2022 Favorsremdesivir Favorscontrol after exclusions
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION PROGRESSION RECOVERY VIRAL CLEARANCE RCTS RCT MORTALITY PEER-REVIEWED After Exclusions ALL STUDIES All Early Late Remdesivir for COVID-19 C19EARLY.COM/S OCT 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] death 4/112 27/260 Improvement, RR [CI] Treatment Control Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Piccicacco 66% 0.34 [0.01-8.32] death 0/82 1/90 Kneidinger 20% 0.80 [0.35-1.82] severe case 6/46 28/172 Tau​2 = 0.27, I​2 = 39.4%, p = 0.026 Early treatment 61% 0.39 [0.17-0.89] 12/519 71/805 61% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] death 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] death 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] death 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] death 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] death 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Schmidt (PSM) -509% 6.09 [2.71-13.7] severe case 43 (n) 434 (n) Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] death 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] death 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] death 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] death 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Malundo -17% 1.17 [0.80-1.70] death 24/115 197/1,100 Bowen -57% 1.57 [1.25-1.97] death 817 (n) 3,814 (n) Raad 42% 0.58 [0.39-0.88] death n/a n/a Oku -40% 1.40 [0.41-4.36] death 3/46 8/172 Tau​2 = 0.06, I​2 = 78.0%, p = 0.0083 Late treatment 14% 0.86 [0.78-0.96] 5,936/41,592 12,015/87,240 14% improvement All studies 14% 0.86 [0.77-0.95] 5,948/42,111 12,086/88,045 14% improvement 43 remdesivir COVID-19 studies c19early.com/s Oct 2022 Tau​2 = 0.06, I​2 = 77.1%, p = 0.0045 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Improvement, RR [CI] Treatment Control Piccicacco 66% 0.34 [0.01-8.32] death 0/82 1/90 Kneidinger 20% 0.80 [0.35-1.82] severe case 6/46 28/172 Tau​2 = 0.77, I​2 = 56.2%, p = 0.15 Early treatment 63% 0.37 [0.10-1.44] 8/407 44/545 63% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Bowen -57% 1.57 [1.25-1.97] death 817 (n) 3,814 (n) Raad 42% 0.58 [0.39-0.88] death n/a n/a Tau​2 = 0.04, I​2 = 74.1%, p = 0.0026 Late treatment 15% 0.85 [0.76-0.94] 5,757/40,371 8,162/68,634 15% improvement All studies 16% 0.84 [0.75-0.93] 5,765/40,778 8,206/69,179 16% improvement 30 remdesivir COVID-19 studies after exclusions c19early.com/s Oct 2022 Tau​2 = 0.04, I​2 = 73.0%, p = 0.0014 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] 4/112 27/260 Improvement, RR [CI] Treatment Control Piccicacco 66% 0.34 [0.01-8.32] 0/82 1/90 Tau​2 = 0.00, I​2 = 0.0%, p = 0.032 Early treatment 66% 0.34 [0.13-0.91] 4/194 28/350 66% improvement Wang (RCT) -9% 1.09 [0.54-2.18] 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] 32 (n) 7,126 (n) Tsuzuki -4% 1.04 [0.98-1.09] 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] 4,441/28,855 5,499/28,855 Jamir (ICU) 8% 0.92 [0.55-1.55] 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] n/a n/a ICU patients Malundo -17% 1.17 [0.80-1.70] 24/115 197/1,100 Bowen -57% 1.57 [1.25-1.97] 817 (n) 3,814 (n) Raad 42% 0.58 [0.39-0.88] n/a n/a Oku -40% 1.40 [0.41-4.36] 3/46 8/172 Tau​2 = 0.05, I​2 = 76.0%, p = 0.0012 Late treatment 16% 0.84 [0.76-0.93] 5,936/41,520 12,015/86,693 16% improvement All studies 16% 0.84 [0.76-0.93] 5,940/41,714 12,043/87,043 16% improvement 39 remdesivir COVID-19 mortality results c19early.com/s Oct 2022 Tau​2 = 0.05, I​2 = 75.4%, p = 0.0011 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fried -37% 1.37 [0.81-2.30] 11/48 1,956/11,673 Improvement, RR [CI] Treatment Control Ullah -250% 3.50 [0.79-15.5] 7/30 2/30 Tsuzuki 2% 0.98 [0.91-1.07] 48/824 98/11,663 Mahajan (RCT) -112% 2.12 [0.41-10.8] 4/34 2/36 Arch (PSM) -68% 1.68 [1.19-2.34] 106/1,498 153/4,602 Kuno (PSM) 0% 1.00 [0.80-1.24] 140/999 140/999 Elec 11% 0.89 [0.45-1.78] 8/38 30/127 Tau​2 = 0.06, I​2 = 59.8%, p = 0.12 Late treatment -24% 1.24 [0.95-1.61] 324/3,471 2,381/29,130 -24% improvement All studies -24% 1.24 [0.95-1.61] 324/3,471 2,381/29,130 -24% improvement 7 remdesivir COVID-19 mechanical ventilation results c19early.com/s Oct 2022 Tau​2 = 0.06, I​2 = 59.8%, p = 0.12 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kuno (PSM) -17% 1.17 [1.00-1.37] 260/999 222/999 Improvement, RR [CI] Treatment Control Elec -72% 1.72 [1.11-2.66] 18/38 35/127 Tau​2 = 0.05, I​2 = 61.8%, p = 0.11 Late treatment -34% 1.34 [0.94-1.92] 278/1,037 257/1,126 -34% improvement All studies -34% 1.34 [0.94-1.92] 278/1,037 257/1,126 -34% improvement 2 remdesivir COVID-19 ICU results c19early.com/s Oct 2022 Tau​2 = 0.05, I​2 = 61.8%, p = 0.11 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Piccicacco 30% 0.70 [0.28-1.72] hosp. 7/82 11/90 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Early treatment 30% 0.70 [0.28-1.72] 7/82 11/90 30% improvement Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Improvement, RR [CI] Treatment Control Ohl (PSM) -100% 2.00 [1.33-3.02] hosp. time 1,172 (n) 1,172 (n) Tau​2 = 0.24, I​2 = 77.6%, p = 0.41 Late treatment -39% 1.39 [0.64-3.01] 0/1,201 0/1,285 -39% improvement All studies -17% 1.17 [0.60-2.28] 7/1,283 11/1,375 -17% improvement 3 remdesivir COVID-19 hospitalization results c19early.com/s Oct 2022 Tau​2 = 0.25, I​2 = 72.0%, p = 0.66 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] death 4/112 27/260 Improvement, RR [CI] Treatment Control Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Piccicacco 66% 0.34 [0.01-8.32] death 0/82 1/90 Kneidinger 20% 0.80 [0.35-1.82] severe case 6/46 28/172 Tau​2 = 0.27, I​2 = 39.4%, p = 0.026 Early treatment 61% 0.39 [0.17-0.89] 12/519 71/805 61% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] death 4/48 2,510/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) SOLIDARITY (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 Solh 47% 0.53 [0.39-0.70] death 63/219 202/424 Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Mulhem -86% 1.86 [0.21-5.24] death 1/8 515/3,211 Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] death 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/37 4/53 Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Madan 44% 0.56 [0.33-0.95] death 23/398 27/260 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Schmidt (PSM) -509% 6.09 [2.71-13.7] severe case 43 (n) 434 (n) Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] death 16/200 29/244 Kurniyanto -460% 5.60 [2.32-13.5] death 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] death 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] death 7/38 29/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Malundo -17% 1.17 [0.80-1.70] death 24/115 197/1,100 Bowen -57% 1.57 [1.25-1.97] death 817 (n) 3,814 (n) Raad 42% 0.58 [0.39-0.88] death n/a n/a Oku -40% 1.40 [0.41-4.36] death 3/46 8/172 Tau​2 = 0.06, I​2 = 78.5%, p = 0.0089 Late treatment 14% 0.86 [0.77-0.96] 5,936/41,563 12,015/87,127 14% improvement All studies 15% 0.85 [0.77-0.95] 5,948/42,082 12,086/87,932 15% improvement 42 remdesivir COVID-19 serious outcomes c19early.com/s Oct 2022 Tau​2 = 0.06, I​2 = 77.7%, p = 0.0048 Effect extraction pre-specified(most serious outcome) Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 29% 0.71 [0.37-1.37] no recov. 43/66 45/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0033 Early treatment 29% 0.71 [0.37-1.37] 43/66 45/60 29% improvement Beigel (RCT) 22% 0.78 [0.67-0.89] no recov. 541 (n) 521 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0005 Late treatment 22% 0.78 [0.67-0.89] 0/541 0/521 22% improvement All studies 24% 0.76 [0.67-0.85] 43/607 45/581 24% improvement 2 remdesivir COVID-19 recovery results c19early.com/s Oct 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goldberg 0% 1.00 [0.92-1.09] viral+ 29 (n) 113 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment 0% 1.00 [0.92-1.09] 0/29 0/113 0% improvement All studies 0% 1.00 [0.92-1.09] 0/29 0/113 0% improvement 1 remdesivir COVID-19 viral clearance result c19early.com/s Oct 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Favors remdesivir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0064 Early treatment 87% 0.13 [0.03-0.59] 2/279 15/283 87% improvement Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Improvement, RR [CI] Treatment Control